New treatment option for patients with chronic hepatitis C

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive patients who have lower fibrosis scores, according to a new study in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news162739824.html">New treatment option for patients with chronic hepatitis C</a></p> <p>A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive patients who have lower fibrosis scores, according to a new study in the June issue of <i>Hepatology</i>, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).</p>